Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
Purity:
95.00%
CAS Number:
[1312299-39-0]
Target:
Others|||Factor Xa
* VAT and and shipping costs not included. Errors and price changes excepted
